Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest Alpha-fetoprotein Stories

2014-01-27 08:27:47

MOUNTAIN VIEW, Calif., Jan. 27, 2014 /PRNewswire/ -- Dr. Shinji Satomura, President, and Dr. Henry Wada, CSO of Wako Life Sciences, Inc., received an award from the Northern California Section of AACC for the scientific and technology contribution to clinical chemistry achieved by the development of the uTASWako i30 Immunoanalyzer. (Photo: http://photos.prnewswire.com/prnh/20140127/LA52677) (Logo: http://photos.prnewswire.com/prnh/20130729/LA53779LOGO-b) "Wako is happy to receive...

2013-07-29 08:26:25

MOUNTAIN VIEW, Calif., July 29, 2013 /PRNewswire/ -- Wako Diagnostics, a division of Wako Life Sciences, Inc., was issued three Class III Medical Device Licences by Health Canada on April 23, 2013 to market the uTASWako i30 instrument with serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) tests for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients...

2013-03-28 08:28:10

ABBOTT PARK, Ill., March 28, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the ARCHITECT AFP test, which may help doctors detect serious birth defects and the progression of testicular cancer, received U.S. Food and Drug Administration (FDA) approval. Biomarkers, such as alpha-fetoprotein (AFP), are substances in the body that physicians can measure to identify the progress of diseases or conditions as well as to evaluate the effectiveness of treatments. AFP has unique traits...

2011-12-02 01:39:15

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma (HCC). The first study found that, if given the choice during a clinical trial, most patients with cirrhosis prefer surveillance over the possibility of non-screening, therefore making a randomized study of HCC screening not feasible. A second study determined...

2011-08-10 06:44:55

(Ivanhoe Newswire) "“ A new genetic analysis could be used to monitor fetal development; allowing clinicians to determine very early in pregnancy if fetal organ systems are developing normally. Using special technology researchers have established the likelihood of focused fetal gene expression analysis of target genes found in amniotic fluid. Using Standardized NanoArray PCR (SNAP) technology, investigators determined that 7 of the 21 genes tested were expressed differently depending...

2011-03-01 08:00:00

RICHMOND, Va., March 1, 2011 /PRNewswire/ -- Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA. The AFP-L3 and DCP assays are intended for use by healthcare professionals as an aid in the risk assessment of patients with chronic liver disease for...

2010-12-16 13:35:54

RFA highly valuable therapy for controlling cancerous nodules Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the...

2010-06-09 21:26:49

Less than 20 percent of qualified patients are regularly monitored A study conducted by researchers at the Baylor College of Medicine found that fewer than 20% of patients with hepatocellular carcinoma (HCC) preceded by cirrhosis were monitored for the development of cancer. Full findings of this study are published in the July issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD). According to the National Cancer Institute, HCC is the fourth most...

2010-03-16 09:32:48

More than three-fourths of hepatocellular carcinoma patients can't have surgery; intra-arterial yttrium-90 gives patients more time, offers minimally invasive treatment An interventional radiology treatment"”the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)"”shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual...

2010-03-05 12:07:08

New standards aim for equitable allocation of available organs Liver transplantation specialists recently convened to address U.S. guidelines for allocation of organs for patients with hepatocellular carcinoma (HCC, liver cancer). Representatives from more than 130 U.S. transplant centers were invited to the conference and participants included 180 leaders in liver transplantation (LT) from the 50 most active centers. Full details of the recommendations developed at the conference are...